NHS England has announced that nearly three quarters of a million patients are set to benefit from new world-leading innovations on the service.
The innovations include a new pre-eclampsia test for pregnant women and an advanced blood test which can cut the time it takes to rule-out a heart attack by 75%. Some of the technology has already reached 300,000 patients across the UK.
The new treatments and tests are being delivered as part of the NHS’ Innovation and Technology Payment programme, which is fast-tracking the roll-out of latest technology across the country, building on progress in the past two years.
NHS England has also confirmed that funding for 10 other new tests and treatments as part of the programme – including a computer programme that creates a digital 3D model of the heart and avoids the need for invasive procedures – will be extended, allowing more patients to benefit.
Dr Sam Roberts, chief executive of the Accelerated Access Collaborative and director of innovation and life sciences for NHS England, said that the programme has been “amazingly successful at getting new tests and treatments to patients, with over 300,000 patients benefitting already, and this year we have another great selection of proven innovations.
“We will build on this success with our commitments set out in the Long Term Plan, to support the latest advances and make it easier for even more patients to benefit from world-class technology.”
As previously set out in the Long Term Plan, the NHS will introduce a new funding mandate for proven health tech products so the NHS can adopt new, cost saving innovations as easily as it already introduces new clinically and cost effective medicines.
Other innovations being supported include SpaceOAR, a hydrogel injected between the prostate and rectum prior to radiotherapy so that the radiation dose to the rectum can be minimised and Gammacore, a hand-held device that delivers mild electrical stimulation to the vagus nerve to block the pain signals that cause cluster headaches.